The Impact of Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on Prediction of Recurrence in Primary Brain Tumor Patients

被引:44
作者
Armstrong, Terri S. [1 ,2 ]
Vera-Bolanos, Elizabeth [2 ]
Gning, Ibrahima [3 ]
Acquaye, Alvina [2 ]
Gilbert, Mark R. [2 ]
Cleeland, Charles [3 ]
Mendoza, Tito [3 ]
机构
[1] Univ Texas Hlth Sci Ctr, Sch Nursing, Dept Integrat Nursing Care, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
关键词
brain tumor; symptoms; tumor progression; QUALITY-OF-LIFE; PROGNOSTIC-FACTORS; CANCER-PATIENTS; SURVIVAL; SEVERITY; GUIDANCE; CRITERIA; PAIN; PROS; FDA;
D O I
10.1002/cncr.25892
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Tumor grade, age, extent of resection, and performance status are established prognostic factors for survival in primary brain tumor (PBT) patients. Development of disease-related symptoms is predictive of tumor recurrence in other cancers but has not been reported in the PBT population. METHODS: A cross-sectional sample of 294 PBT patients participated. Progression was based on the radiologist report of the magnetic resonance imaging (MRI). The relation of clinical variables (age, extent of resection, tumor grade, and Karnofsky performance status [KPS]) and MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) mean symptom and interference sub-scales with progression was examined using logistic regression. RESULTS: The study enrolled more men (60%, n =175); median age was 46 years. The majority had less than a gross total resection (n = 186, 64%), and a good KPS (KPS >= 90) (N = 208). The majority had a grade 3 or 4 tumor (n = 199) and 24% of patients had recurrence. Tumor grade and activity-related interference were significantly related to progression. Patients with tumor grade 4 were 2.4 times more likely to have recurrence (95% Cl, 1.2-5.; P < .015). Patients with significant (ratings of >= 5) activity-related interference were 3.8 times more likely to have recurrence (95% Cl, 2.14-6.80; P < .001). Mean activity-related score was 4.8 for those with progression on MRI and 2.2 for those with stable disease. CONCLUSIONS: Significant activity-related interference and tumor grade were associated with recurrence but not KPS, age, or extent of resection. These results provide preliminary support for the use of symptom interference in assessment of disease status. Because the authors used a cross-sectional sample, future studies evaluating change over time are needed. Cancer (C) 2011;117:3222-8. 2077 American Cancer Society.
引用
收藏
页码:3222 / 3228
页数:7
相关论文
共 25 条
[1]   Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) [J].
Armstrong, T. S. ;
Mendoza, T. ;
Gring, I. ;
Coco, C. ;
Cohen, M. Z. ;
Eriksen, L. ;
Hsu, Ming-Ann ;
Gilbert, M. R. ;
Cleeland, C. .
JOURNAL OF NEURO-ONCOLOGY, 2006, 80 (01) :27-+
[2]   Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors [J].
Armstrong, TS ;
Cohen, MZ ;
Eriksen, LR ;
Hickey, JV .
JOURNAL OF NURSING SCHOLARSHIP, 2004, 36 (03) :197-206
[3]   The FDA guidance for industry on PROs: the point of view of a pharmaceutical company [J].
Arpinelli, Fabio ;
Bamfi, Francesco .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
[4]   Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status [J].
Brandes, Alba A. ;
Tosoni, Alicia ;
Franceschi, Enrico ;
Sotti, Guido ;
Frezza, Giampiero ;
Amista, Pietro ;
Morandi, Luca ;
Spagnolli, Federica ;
Ermani, Mario .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1275-1279
[5]   Pseudoprogression and pseudoresponse in the treatment of gliomas [J].
Brandsma, Dieta ;
van den Bent, Martin J. .
CURRENT OPINION IN NEUROLOGY, 2009, 22 (06) :633-638
[6]  
Cella D, 2006, ONCOLOGY-NY, V20, P436
[7]   Dimensions of the impact of cancer pain in a four country sample: New information from multidimensional scaling [J].
Cleeland, CS ;
Nakamura, Y ;
Mendoza, TR ;
Edwards, KR ;
Douglas, J ;
Serlin, RC .
PAIN, 1996, 67 (2-3) :267-273
[8]  
Cleeland CS, 2000, CANCER-AM CANCER SOC, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO
[9]  
2-V
[10]   Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker [J].
Jain, Rajan ;
Scarpace, Lisa M. ;
Ellika, Shehanaz ;
Torcuator, Roy ;
Schultz, Lonni R. ;
Hearshen, David ;
Mikkelsen, Tom .
JOURNAL OF NEURO-ONCOLOGY, 2010, 96 (03) :423-431